Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2019 Nov;17(12):2497-2505.e1.
doi: 10.1016/j.cgh.2018.12.040. Epub 2019 Jan 6.

Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis

David M Faleck  1 , Adam Winters  1 , Shreya Chablaney  1 , Preeti Shashi  2 , Joseph Meserve  3 , Aaron Weiss  4 , Satimai Aniwan  5 , Jenna L Koliani-Pace  6 , Gursimran Kochhar  2 , Brigid S Boland  3 , Siddharth Singh  3 , Robert Hirten  1 , Eugenia Shmidt  7 , Varun Kesar  8 , Karen Lasch  9 , Michelle Luo  9 , Matthew Bohm  10 , Sashidhar Varma  10 , Monika Fischer  10 , David Hudesman  11 , Shannon Chang  11 , Dana Lukin  4 , Keith Sultan  12 , Arun Swaminath  8 , Nitin Gupta  13 , Corey A Siegel  6 , Bo Shen  2 , William J Sandborn  3 , Sunanda Kane  5 , Edward V Loftus Jr  5 , Bruce E Sands  1 , Jean-Frederic Colombel  1 , Parambir S Dulai  14 , Ryan Ungaro  15
Affiliations
Multicenter Study

Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis

David M Faleck et al. Clin Gastroenterol Hepatol. 2019 Nov.

Abstract

Background & aims: Patients with Crohn's disease (CD), but not ulcerative colitis (UC), of shorter duration have higher rates of response to tumor necrosis factor (TNF) antagonists than patients with longer disease duration. Little is known about the association between disease duration and response to other biologic agents. We aimed to evaluate response of patients with CD or UC to vedolizumab, stratified by disease duration.

Methods: We analyzed data from a retrospective, multicenter, consortium of patients with CD (n = 650) or UC (n = 437) treated with vedolizumab from May 2014 through December 2016. Using time to event analyses, we compared rates of clinical remission, corticosteroid-free remission (CSFR), and endoscopic remission between patients with early-stage (≤2 years duration) and later-stage (>2 years) CD or UC. We used Cox proportional hazards models to identify factors associated with outcomes.

Results: Within 6 months initiation of treatment with vedolizumab, significantly higher proportions of patients with early-stage CD, vs later-stage CD, achieved clinical remission (38% vs 23%), CSFR (43% vs 14%), and endoscopic remission (29% vs 13%) (P < .05 for all comparisons). After adjusting for disease-related factors including previous exposure to TNF antagonists, patients with early-stage CD were significantly more likely than patients with later-stage CD to achieve clinical remission (adjusted hazard ratio [aHR], 1.59; 95% CI, 1.02-2.49), CSFR (aHR, 3.39; 95% CI, 1.66-6.92), and endoscopic remission (aHR, 1.90; 95% CI, 1.06-3.39). In contrast, disease duration was not a significant predictor of response among patients with UC.

Conclusions: Patients with CD for 2 years or less are significantly more likely to achieve a complete response, CSFR, or endoscopic response to vedolizumab than patients with longer disease duration. Disease duration does not associate with response vedolizumab in patients with UC.

Keywords: Inflammatory Bowel Disease; Integrin; Monoclonal Antibody Therapy; Time.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Cumulative rates of remission stratified by disease duration ≤2 years or >2 years. (A) Clinical remission. (B) Corticosteroid-free remission. (C) Endoscopic remission.
See this image and copyright information in PMC

Comment in

  • Short Disease Duration Does Not Always Indicate Early Crohn's Disease.
    Rodríguez-Lago I, Barreiro-de Acosta M. Rodríguez-Lago I, et al. Clin Gastroenterol Hepatol. 2019 Jul;17(8):1646. doi: 10.1016/j.cgh.2019.01.017. Epub 2019 Jan 18. Clin Gastroenterol Hepatol. 2019. PMID: 30664948 No abstract available.
  • Reply.
    Faleck D, Dulai P, Ungaro R. Faleck D, et al. Clin Gastroenterol Hepatol. 2019 Jul;17(8):1646-1647. doi: 10.1016/j.cgh.2019.02.003. Epub 2019 Feb 13. Clin Gastroenterol Hepatol. 2019. PMID: 30771499 No abstract available.

References

    1. Torres J, Mehandru S, Colombel JF, et al. Crohn’s disease. Lancet 2017;389:1741–1755. - PubMed
    1. Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet 2017;389:1756–1770. - PMC - PubMed
    1. Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology 2010; 139:1147–1155. - PMC - PubMed
    1. Pariente B, Mary JY, Danese S, et al. Development of the Lemann index to assess digestive tract damage in patients with Crohn’s disease. Gastroenterology 2015;148:52–63. - PubMed
    1. Torres J, Billioud V, Sachar DB, et al. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis 2012;18:1356–1363. - PubMed

Publication types